Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | DPYD deficiency in patients with severe toxicity after 5-fluorouracil

Hans Prenen • 22 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer General 5-fluorouracil

Hans Prenen, MD, PhD, UZ Leuven, Leuven, Belgium, discusses the results of a retrospective single-center study evaluating the prevalence of dihydropyrimidine dehydrogenase (DPYD) deficiency in patients with severe toxicity after 5-fluorouracil in solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Hans Prenen

1:52
Patient-derived organoids as models for chemoradiation response prediction in GI malignancies
Hans Prenen • 22 Jan 2021
1:01
Improving the efficacy of immunotherapy using anti-angiogenic agents in GI malignancies
Hans Prenen • 22 Jan 2021
2:26
alloSHRINK: Phase I first-in-human study evaluating CYAD-101, an allogeneic CAR-T in mCRC
Hans Prenen • 22 Jan 2021

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals